Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SUPERNUS PHARMACEUTICALS, INC.

(SUPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Supernus Pharmaceuticals : Targeted in Ransomware Incident - Form 8-K

11/26/2021 | 06:20am EST

Supernus Pharmaceuticals Targeted in Ransomware Incident

The attack had no significant impact on the business and did not cause any significant disruption to Company's operations

No ransom payments have been made by the Company

ROCKVILLE, Md., Nov. 24, 2021 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company, today announced that it was the recent target of a ransomware attack. The attack had no significant impact on the business and did not cause any serious disruption to the Company's operations. The Company continues to operate without interruption and does not currently anticipate paying any ransom amounts to any criminal ransomware group.

The Company currently believes the incident began around mid-November, 2021. Based on the preliminary results of the ongoing investigation, the Company believes the criminal ransomware group encrypted certain files on the Company's systems, deployed malware to impede access to the Company's systems, and thereafter threatened to publish certain data copied from the Company's systems. Upon detection of the ransomware, the Company notified government authorities, engaged cybersecurity experts and its outside law firm, and commenced its recovery process. The Company successfully recovered the impacted files and has taken additional steps designed to further protect its networks and files.

To date, the Company has not paid any ransom and has been able to restore all of the information encrypted by the criminal ransomware group.

Although to date the Company's business and operations have not been significantly impacted by the incident, there is no assurance that further attacks may not significantly impact the Company's business or operations and that information improperly obtained by the criminal ransomware group may not be exploited by the criminal ransomware group or other third parties. The Company will take appropriate action to protect any stolen confidential information and will continue to investigate the incident and monitor the situation going forward.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson's disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson's disease, epilepsy, depression and rare CNS disorders.

For more information, please visit www.supernus.com.

CONTACTS:

Jack A. Khattar, President and CEO

Timothy C. Dec, Senior Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

or

INVESTOR CONTACT:

Peter Vozzo

ICR Westwicke

Office: (443) 213-0505

Mobile: (443) 377-4767

Email: peter.vozzo@westwicke.com

Disclaimer

Supernus Pharmaceuticals Inc. published this content on 26 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 November 2021 11:19:09 UTC.


ę Publicnow 2021
All news about SUPERNUS PHARMACEUTICALS, INC.
01/24Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)
AQ
2021Supernus Pharmaceuticals Resubmits New-Drug Application to FDA for Apomorphine Infusion..
MT
2021Supernus Pharmaceuticals Resubmits NDA for Parkinson's Disease Treatment
DJ
2021SUPERNUS PHARMACEUTICALS : Resubmits NDA for SPN-830 Apomorphine Infusion Device - Form 8-..
PU
2021SUPERNUS PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
2021Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
GL
2021Supernus Pharmaceuticals, Inc. Resubmits NDA for SPN-830 Apomorphine Infusion Device
CI
2021Supernus Pharmaceuticals Shares Climb After Jefferies Resumes Coverage at Buy
MT
2021Jefferies Reinstates Supernus Pharmaceuticals at Buy With $44 Price Target
MT
2021SUPERNUS PHARMACEUTICALS : Targeted in Ransomware Incident - Form 8-K
PU
More news
Analyst Recommendations on SUPERNUS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 569 M - -
Net income 2021 62,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 24,9x
Yield 2021 -
Capitalization 1 561 M 1 561 M -
Capi. / Sales 2021 2,74x
Capi. / Sales 2022 2,21x
Nbr of Employees 563
Free-Float 95,8%
Chart SUPERNUS PHARMACEUTICALS, INC.
Duration : Period :
Supernus Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUPERNUS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 29,35 $
Average target price 36,50 $
Spread / Average Target 24,4%
EPS Revisions
Managers and Directors
Jack A. Khattar President, CEO, Secretary & Director
Timothy C. Dec Chief Financial Officer & Senior Vice President
Charles W. Newhall Chairman
Padmanabh P. Bhatt Chief Scientific Officer & Senior Vice President
Frank Mottola Senior VP-Quality, GMP Operations & IT
Sector and Competitors